Sanofi is a French pharmaceutical company created in 2004 by the merger of Sanofi-Synthélabo and Aventis. With sales of EUR 36.1 billion in 2019 and more than 100,000 employees worldwide, Sanofi is one of the largest pharmaceutical companies in the world in terms of sales.
P/E ratio for Sanofi (SNY)
P/E ratio as of March 2023 (TTM): 19.1
According to Sanofi's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 19.1377. At the end of 2013 the company had a P/E ratio of 28.5.
P/E ratio history for Sanofi from 2003 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2013 | 28.5 | 46.4% |
| 2012 | 19.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 22.4 | 17.30% | 🇺🇸 USA |
 Novartis NVS | 28.3 | 47.73% | 🇨🇭 Switzerland |
 Pfizer PFE | 7.19 | -62.44% | 🇺🇸 USA |
 Novo Nordisk NVO | 45.7 | 138.67% | 🇩🇰 Denmark |
 Abbott Laboratories ABT | 23.0 | 20.00% | 🇺🇸 USA |
 Eli Lilly LLY | 50.0 | 161.51% | 🇺🇸 USA |
 Merck MRK | 18.3 | -4.32% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 25.1 | 30.98% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 4.43 | -76.83% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | -4.17 | -121.79% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.